INBRAIN Neuroelectronics announces FDA Breakthrough Device designation for its graphene-based intelligent network modulation platform
A first-of-a-kind device, the INBRAIN Intelligent Network Modulation System is designed to offer a new treatment option for patients with Parkinson’s disease. It harnesses the properties of graphene and the power of machine learning software to provide highly targeted and adaptive neuroelectronic therapy. INBRAIN Neuroelectronics is a health-tech company that originated as a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, with the participation of the IMB-CNM-CSIC.